TABLE 1.
Baseline clinical characteristics of patients according to REALYSA inclusion
| Clinical Characteristics | All Patients n = 278 (%) |
Included in REALYSA n = 151 (%) |
Nonincluded in REALYSA n = 127 (%) |
|---|---|---|---|
| Age ≥60 years | 168 (60%) | 82 (54%) | 86 (68%) |
| Gender: Male | 159 (57%) | 91 (60%) | 68 (54%) |
| Lymphoma Subtype | |||
| DLBCL | 104 (37%) | 59 (39%) | 45 (35%) |
| FL | 56 (20%) | 33 (22%) | 23 (18%) |
| HL | 46 (17%) | 26 (17%) | 20 (16%) |
| MZL | 35 (13%) | 15 (10%) | 20 (16%) |
| T-Cell Lymphoma | 19 (7%) | 6 (4%) | 13 (10%) |
| MCL | 16 (6%) | 10 (7%) | 6 (5%) |
| Burkitt lymphoma | 2 (1%) | 2 (1%) | 0 (0%) |
| Performance Status (n = 277) | |||
| 0-1 | 222 (80%) | 130 (86%) | 92 (72%) |
| 2-4 | 55 (20%) | 21 (14%) | 34 (27%) |
| Ann Arbor stage (n = 277) | |||
| I-II | 70 (25%) | 36 (24%) | 34 (27%) |
| III-IV | 207 (75%) | 115 (76%) | 92 (72%) |
| B symptoms (n = 277) | 90 (32%) | 42 (28%) | 48 (38%) |
| LDH level (UI/L) > Normal (n = 275) | 190 (68%) | 99 (66%) | 91 (72%) |
| Albumin level < 40 g/L (n = 267) | 145 (52%) | 66 (44%) | 79 (62%) |
| Charlson Comorbidity Index (CCI) | |||
| 0 | 178 (64%) | 100 (66%) | 78 (61%) |
| 1 | 49 (18%) | 28 (19%) | 21 (17%) |
| 2 | 25 (9%) | 12 (8%) | 13 (10%) |
| >2 | 26 (9%) | 11 (7%) | 15 (12%) |
| Previous solid cancer | 36 (13%) | 14 (9%) | 22 (17%) |
| ≥3 concomitant medications | 92 (33%) | 42 (28%) | 50 (39%) |
| Delay since the first symptoms (n = 275) | |||
| <3 months | 144 (52%) | 71 (47%) | 73 (58%) |
| 3-6 months | 73 (26%) | 50 (33%) | 23 (18%) |
| >6 months | 58 (21%) | 29 (20%) | 29 (23%) |
| Day of the first consultation or hospitalization | |||
| Monday-Thursday | 239 (86%) | 132 (87%) | 107 (84%) |
| Friday-Sunday | 39 (14%) | 19 (13%) | 20 (16%) |
| Access to Haematology Department (n = 276) | |||
| Hospitalization | 54 (19%) | 21 (14%) | 33 (26%) |
| Consultation | 222 (80%) | 130 (86%) | 92 (72%) |
| Distance from Hospital (km) (n = 277) | |||
| ≤15 | 117 (42%) | 57 (38%) | 60 (47%) |
| 16-59 | 95 (34%) | 61 (40%) | 34 (27%) |
| ≥60 | 65 (23%) | 33 (22%) | 32 (25%) |
| Therapeutic intention | |||
| Curative intent | 251 (90%) | 146 (97%) | 105 (83%) |
| Watch and Wait | 19 (7%) | 5 (3%) | 14 (11%) |
| Palliative intent | 8 (3%) | 0 (0%) | 8 (6%) |
Abbreviations: DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; HL, Hodgkin lymphoma; MZL, marginal zone lymphoma; MCL, mantle cell lymphoma; LDH, lactate dehydrogenase.